hVIVO (LON:HVO) Shares Up 13% - Time to Buy?

Key Points

• hVIVO plc shares surged by 13% on Monday, closing at GBX 7.80, with trading volume increasing by 223% compared to normal levels.
• Analysts have mixed ratings for hVIVO, with Peel Hunt maintaining an "add" rating at a target price of GBX 21, while Shore Capital lowered theirs from GBX 35 to GBX 25, but still rated it a “buy.”
• The company reported a net margin of 25.96% and a return on equity of 47.93%, with an average projected earnings per share of 1.55 for the current fiscal year.

hVIVO plc (LON:HVO - Get Free Report)'s stock price shot up 13% on Monday . The company traded as high as GBX 8 ($0.11) and last traded at GBX 7.80 ($0.10). 9,588,585 shares traded hands during trading, an increase of 223% from the average session volume of 2,969,923 shares. The stock had previously closed at GBX 6.90 ($0.09).

Analyst Ratings Changes

A number of research firms have weighed in on HVO. Peel Hunt restated an "add" rating and set a GBX 21 price objective on shares of hVIVO in a research note on Tuesday, July 29th. Shore Capital reduced their price objective on shares of hVIVO from GBX 35 to GBX 25 and set a "buy" rating for the company in a research note on Tuesday, September 23rd. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, hVIVO has an average rating of "Buy" and an average target price of GBX 23.

hVIVO Stock Performance

The business's fifty day moving average price is GBX 9.24 and its 200-day moving average price is GBX 11.96. The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The stock has a market cap of £54.98 million, a PE ratio of 1,038.96 and a beta of 0.97.

hVIVO (LON:HVO - Get Free Report) last announced its quarterly earnings results on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. As a group, equities research analysts forecast that hVIVO plc will post 1.5492958 EPS for the current fiscal year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.